Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15293824 | 0.86 | DGAT1 (0.54) | DGAT1AAK1CXCR2HIF1AUCHL1 | |
| SCHEMBL10176466 | 0.81 | DGAT1 (0.70) | DGAT1AAK1HIF1A | |
| SCHEMBL10177891 | 0.78 | DGAT1 (0.57) | DGAT1AAK1CXCR2HIF1AUCHL1 | |
| SCHEMBL9936493 | 0.75 | KDM4E (0.50) | DGAT1CYP1A2CYP2C9 | |
| SCHEMBL15293830 | 0.75 | DGAT1 (0.65) | DGAT1AAK1UCHL1LIPE | |
| SCHEMBL2719235 | 0.74 | L3MBTL1 (0.42) | CXCR2HIF1AUCHL1 | |
| SCHEMBL2132595 | 0.74 | CXCR2 (0.37) | AAK1CXCR2HIF1AUCHL1 | |
| SCHEMBL25862368 | 0.73 | DGAT1 (0.48) | DGAT1AAK1CXCR2UCHL1LIPE | |
| SCHEMBL9937184 | 0.73 | DGAT1 (0.40) | DGAT1AAK1UCHL1 | |
| SCHEMBL17452560 | 0.73 | UCHL1 (0.41) | CXCR2HIF1AUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-2651915-B1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-25 | — | — | EP | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2012081736-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885AAK1 1147/4885CXCR2 4198/4885 |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885AAK1 1147/4885CXCR2 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.